Cell Cycle (pCdk/pHH3/Actin) WB Cocktail
Be the first to review this product! Submit a review
|
(17 Publications)
- WB
Supplier Data
Western blot - Cell Cycle (pCdk/pHH3/Actin) WB Cocktail (AB136810)
Western blot – ab136810 Cell Cycle Western Blot Cocktail Cdk2 pTyr15 and Histone H3 pSer10 bands are present in asynchronous cells. Cdk2 pTyr15 is elevated in G1/S arrested cells. Conversely, Histone H3 pSer10 is elevated in G2/M arrested cells. Primary antibody : All lanes Cell 250X Cell Cycle WB Cocktail diluted to 1X in 4% milk/PBS. Lane 1 : HeLa lysate; Untreated, asynchronous cells Lane 2 : HeLa lysate; G1/S arrested cells (thymidine treatment) Lane 3 : HeLa lysate; G2/M arrested cells (sequential thymidine and nocodazole treatments) All lysates at 15 µg per lane. Lysates are ab136811 HeLa Cell Cycle Lysates Secondary antibody : All lanes anti-rabbit-HRP. Predicted band size : 42, 33, 17 kDa.
false
- WB
Supplier Data
Western blot - Cell Cycle (pCdk/pHH3/Actin) WB Cocktail (AB136810)
Western blot – ab136810 Cell Cycle Western Blot Cocktail Cdk2 pTyr15 intensity decreases and Histone H3 pSer10 intensity increases as a function of Paclitaxel concentration. Equivalent protein loading is indicated by the equal actin intensity across samples. Primary antibody : All lanes Cell 250X Cell Cycle WB Cocktail diluted to 1X in 4% milk/PBS. Lane 1 : HeLa lysate; Control treatment Lane 2 : HeLa lysate; 0.25 nM Paclitaxel, 24 h treatment Lane 3 : HeLa lysate; 5 nM Paclitaxel, 24 h treatment Lane 4 : HeLa lysate; 100 nM Paclitaxel, 24 h treatment Lane 5 : HeLa lysate; 2000 nM Paclitaxel, 24 h treatment All lysates at 15 µg per lane. Secondary antibody : All lanes anti-rabbit-HRP. Predicted band size : 42, 33, 17 kDa.
false
- WB
Supplier Data
Western blot - Cell Cycle (pCdk/pHH3/Actin) WB Cocktail (AB136810)
Western blot – ab136810 Cell Cycle Western Blot Cocktail Hydroxyurea, Camptothecin and Etoposide treatments cause a G1/S-like arrest as judged by the increase in Cdk2 pTyr15 and decrease in Histone H3 pSer10 bands relative to control. In contrast, Paclitaxel causes a G2/M like arrest judged by the decreased Cdk2 pTyr15 and increased Histone H3 pSer10 bands. Primary antibody : All lanes Cell 250X Cell Cycle WB Cocktail diluted to 1X in 4% milk/PBS. Lane 1 : HeLa lysate; Control treatment Lane 2 : HeLa lysate; 5 mM Hydroxyurea, 24 h treatment Lane 3 : HeLa lysate; 5 µM Camptothecin, 24 h treatment Lane 4 : HeLa lysate; 1.5 µM Etoposide, 24 h treatment Lane 5 : HeLa lysate; 2000 nM Paclitaxel, 24 h treatment All lysates at 15 µg per lane. Secondary antibody : All lanes anti-rabbit-HRP. Predicted band size : 42, 33, 17 kDa.
false
Complementary Products
Multiplex Kits
AB228528
Cell Cycle (Cdk2, Cdk6, Cyclin B1, Cyclin D1, p21, p27 KIP 1) Antibody Sampler Panel
Recombinant
- 0
- 0
Reagents, Controls & Accessories
AB136812
Apoptosis Western Blot Cocktail (pro/p17-caspase-3, cleaved PARP1, muscle actin)
- 0
- 0
Primary Antibodies
AB8227
Anti-beta Actin antibody - Loading Control
BOND RX™ Validated|Lab Essentials
- 5
- 104
Reactivity data
Product details
The Cell Cycle western blot cocktail (ab136810) is designed to provide a rapid assessment of cell cycle distribution based on molecular markers for the G1/S and M phases of the cell cycle. This is a mixture of three specific rabbit monoclonal primary antibodies targeting phospho-cdk2 Tyr15, phospho Histone H3 Ser10 and beta-actin. Cyclin-dependent kinase 2 (Cdk2) is maintained in an inactive state in G1/S by inhibitory phosphorylation on Tyr15. Histone H3 is phosphorylated at Ser10 when chromosomes condense during mitosis. Hence, elevated phospho-cdk2 Tyr15 indicates G1/S arrested cells and elevated phospho Histone H3 Ser10 indicates M-phase arrested cells when compared to asynchronous cycling control cells. An anti- Actin antibody is included as a loading control. These three readouts are easily resolved by western blot given their different molecular weights.
The recommended dilution for this cocktail is 1:250.
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Target data
Publications (17)
Recent publications for all applications. Explore the full list and refine your search
Breast cancer (Tokyo, Japan) 32:457-469 PubMed39979691
2025
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in cell and developmental biology 12:1481491 PubMed39474351
2024
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 25: PubMed39000120
2024
Applications
Unspecified application
Species
Unspecified reactive species
Cancer science 115:1866-1880 PubMed38494600
2024
Applications
Unspecified application
Species
Unspecified reactive species
Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology 22:2037-2053 PubMed37166570
2023
Applications
Unspecified application
Species
Unspecified reactive species
Oncology 100:101-113 PubMed34724663
2021
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 11:19178 PubMed34584127
2021
Applications
Unspecified application
Species
Unspecified reactive species
Molecular cell 81:3065-3081.e12 PubMed34297911
2021
Applications
Unspecified application
Species
Unspecified reactive species
Cell cycle (Georgetown, Tex.) 20:903-913 PubMed33870855
2021
Applications
Unspecified application
Species
Unspecified reactive species
Neural regeneration research 15:1894-1902 PubMed32246638
2020
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com